本帖最后由 maicon08 于 2023-4-28 15:12 编辑
, l) y2 a4 g, n6 D- f* A$ b! M3 [: `" z/ @
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。- M( [# p* v! U
6 ?% O& Q* z+ f9 |0 T0 w. J8 f2 vhttps://www.163.com/dy/article/I3BTTPRD053438SI.html
+ w& j+ x! s* `! U2 A4 o9 ^0 W# M' p. ^# i0 l; z
* H& c3 r& J8 P6 Y y. s% U! U
在研疗法-免疫治疗
( p; U! l3 D$ _, f8 r; D3 ODevelopmental Therapeutics—Immunotherapy
+ R* x! F5 f4 H. e U 9 c9 j2 @% b: ]9 _5 r, c
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
: e: r, x5 j4 x8 H7 \! J1 m- }' [' z
在研疗法-分子靶向药物和肿瘤生物学
, ^5 _# X3 L' Q8 Y Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology * k( A7 T ^5 V3 U0 F$ W! r
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
4 A; w" r0 v! X: `0 M v0 t- M
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
; D7 u9 O: x, I" R& x" c
胃肠道肿瘤-结直肠癌和肛门癌
+ e9 |# k$ N6 Y* |0 C7 K Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
" }& J7 x' k F) {! ]
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
) A* g4 _8 Q, @' A摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
7 ?$ Z, u" J( N
妇科肿瘤 Gynecologic Cancer , n# x2 D4 f- B* O: I: v
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
( _" \% w, d* _4 |" w/ R& n
头颈肿瘤
8 p+ [3 M8 {5 m Head and Neck Cancer
% q Z9 d0 q" j( V) Y- c摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
( j5 G/ R& G$ O& [+ k
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
4 O: e. l7 g" e$ c9 \, q' K
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 ! h" H5 y. z/ ^1 x! S5 ]" ~ H
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia ( Q7 k6 V6 t0 }2 u. g! ]3 W9 u
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
' r/ M, M6 e+ S, i
血液系统恶性肿瘤-浆细胞疾病- w( q/ k) V: S+ @
Hematologic Malignancies—Plasma Cell Dyscrasia
8 p+ s+ A( u" }4 J5 N+ x b摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 # D8 a0 ?' U$ }7 l! i2 {" B6 u
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
7 B/ t: j" k5 E2 |* R9 X$ j, c. w Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
" C2 x% U! ]8 B( {摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 ) Z5 f( J; z( F1 y1 E0 f/ [+ s
肺癌-转移性非小细胞肺癌
2 r3 d! k9 S5 x) } Lung Cancer—Non-Small Cell Metastatic
* {9 }8 x# p) D1 U! N7 ?4 k* } {摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
9 N) i+ |3 E+ M: t4 H
9 z8 j5 E z& u. c4 T摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 8 r% X2 X: _+ y2 N6 t5 N
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
6 @- }! K* C E& ]; G* N9 n7 y" s' \
黑色素瘤/皮肤癌
A; D& E+ _8 [4 ? Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 # z- ?: Q$ e# J/ A" D2 H
快速摘要报告+ j) M! m5 R" n" G& R; j
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
. i V6 i6 Y1 Q9 n" ~% r
临床科学研讨会
0 P1 K) w$ l# @0 r, K6 e$ N Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 5 C* C" _$ r* b" y: O- C
9 W5 W1 O8 B! W$ X. m6 q
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
